Inventor · disambiguated record
Bruce L. Levine
Also filed as: LEVINE BRUCE · LEVINE BRUCE L
33 granted patents·21 pending applications·3,091 citations·filing 1998–2025
98Inventor score
Top patents by PatentIndex Score
54 records- 0199US9540445B2Compositions and methods for treatment of cancerUNIV PENNSYLVANIA·Filed 2016·Granted Jan 10, 2017·99 cites·30 claims
- 0299US9518123B2Compositions and methods for treatment of cancerUNIV PENNSYLVANIA·Filed 2016·Granted Dec 13, 2016·92 cites·26 claims
- 0399US9481728B2Compositions and methods for treatment of cancerUNIV PENNSYLVANIA·Filed 2015·Granted Nov 1, 2016·100 cites·30 claims
- 0499US9464140B2Compositions and methods for treatment of cancerUNIV PENNSYLVANIA·Filed 2016·Granted Oct 11, 2016·117 cites·28 claims
- 0599US9328156B2Use of chimeric antigen receptor-modified T cells to treat cancerUNIV PENNSYLVANIA·Filed 2013·Granted May 3, 2016·127 cites·15 claims
- 0699US9102761B2Compositions for treatment of cancerUNIV PENNSYLVANIA·Filed 2014·Granted Aug 11, 2015·250 cites·30 claims
- 0799US9102760B2Compositions for treatment of cancerUNIV PENNSYLVANIA·Filed 2014·Granted Aug 11, 2015·254 cites·30 claims
- 0899US9101584B2Methods for treatment of cancerUNIV PENNSYLVANIA·Filed 2014·Granted Aug 11, 2015·250 cites·30 claims
- 0999US8975071B1Compositions for treatment of cancerUNIV PENNSYLVANIA·Filed 2014·Granted Mar 10, 2015·255 cites·17 claims
- 1099US8916381B1Methods for treatment of cancerUNIV PENNSYLVANIA·Filed 2014·Granted Dec 23, 2014·276 cites·28 claims
- 1199US8911993B2Compositions for treatment of cancerUNIV PENNSYLVANIA·Filed 2013·Granted Dec 16, 2014·474 cites·21 claims
- 1299US8906682B2Methods for treatment of cancerUNIV PENNSYLVANIA·Filed 2013·Granted Dec 9, 2014·507 cites·30 claims
- 1398US9499629B2Use of chimeric antigen receptor-modified T-cells to treat cancerJUNE CARL H·Filed 2011·Granted Nov 22, 2016·151 cites·53 claims
- 1495US10603378B2Toxicity management for anti-tumor activity of CARsUNIV PENNSYLVANIA·Filed 2018·Granted Mar 31, 2020·10 cites·28 claims
- 1595US9572836B2Methods for assessing the suitability of transduced T cells for administrationUNIV PENNSYLVANIA·Filed 2013·Granted Feb 21, 2017·33 cites·14 claims
- 1694US10829735B2Methods for improving the efficacy and expansion of immune cellsUNIV PENNSYLVANIA·Filed 2016·Granted Nov 10, 2020·14 cites·28 claims
- 1794US10273300B2Methods of making chimeric antigen receptor-expressing cellsUNIV PENNSYLVANIA·Filed 2015·Granted Apr 30, 2019·26 cites·28 claims
- 1892US11273219B2Toxicity management for anti-tumor activity of CARsUNIV PENNSYLVANIA·Filed 2018·Granted Mar 15, 2022·4 cites·20 claims
- 1991US12240884B2Methods for improving the efficacy and expansion of immune cellsNOVARTIS AG·Filed 2020·Granted Mar 4, 2025·2 cites·24 claims
- 2091US9133436B2ICOS critically regulates the expansion and function of inflammatory human Th17 cellsRILEY JAMES L·Filed 2011·Granted Sep 15, 2015·16 cites·30 claims
- 2184US11648270B2Methods for treating chronic lymphocytic leukemia (CLL)UNIV PENNSYLVANIA·Filed 2019·Granted May 16, 2023·1 cites·20 claims
- 2284US8129185B2Regulatory T cells and their use in immunotherapy and suppression of autoimmune responsesBLAZAR BRUCE·Filed 2009·Granted Mar 6, 2012·3 cites·2 claims
- 2384US7651855B2Regulatory T cells and their use in immunotherapy and suppression of autoimmune responsesUNIV PENNSYLVANIA·Filed 2004·Granted Jan 26, 2010·11 cites·14 claims
- 2481US2023302052A1Methods for treating chronic lymphocytic leukemia (cll)UNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 2580US9994818B2ICOS critically regulates the expansion and function of inflammatory human Th17 cellsUNIV PENNSYLVANIA·Filed 2015·Granted Jun 12, 2018·2 cites·5 claims
- 2680US9181526B2Regulatory T cells and their use in immunotherapy and suppression of autoimmune responsesBLAZAR BRUCE·Filed 2012·Granted Nov 10, 2015·2 cites·14 claims
- 2780US9161971B2Method for treating chronic lymphocytic leukemia (CC)JUNE CARL H·Filed 2012·Granted Oct 20, 2015·4 cites·12 claims
- 2879US2023399615A1Icos critically regulates the expansion and function of inflammatory human th17 cellsUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 2978US2024261328A1Use of cart19 to deplete normal b cells to induce toleranceUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 3076US7718196B2Rapamycin-resistant T cells and therapeutic uses thereofUS GOV HEALTH & HUMAN SERV·Filed 2005·Granted May 18, 2010·3 cites·17 claims
- 3175US2023013642A1Toxicity Management for Anti-Tumor Activity of CARsUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 3275US2023295296A1Methods of making chimeric antigen receptor-expressing cellsNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3374US8415150B2Methods for treating progressive multifocal leukoencephalopathy (PML)JUNE CARL H·Filed 2010·Granted Apr 9, 2013·2 cites·12 claims
- 3474US2023034117A1Compositions and methods for regulating car t cellsUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 3572US10046008B2Methods for treating chronic lymphocytic leukemia (CLL)UNIV PENNSYLVANIA·Filed 2015·Granted Aug 14, 2018·1 cites·15 claims
- 3672US2024398913A1Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cellsNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3771US11001805B2ICOS critically regulates the expansion and function of inflammatory human Th17 cellsUNIV PENNSYLVANIA·Filed 2018·Granted May 11, 2021·0 cites·4 claims
- 3869US2025230217A1Methods for improving the efficacy and expansion of immune cellsNOVARTIS AG·Filed 2025·Application pending·0 cites
- 3969US2018258391A1Compositions and Methods for Treatment of CancerUNIV PENNSYLVANIA·Filed 2017·Application pending·0 cites
- 4068US8075921B2Rapamycin-resistant T cells and therapeutic uses thereofFOWLER DANIEL H·Filed 2010·Granted Dec 13, 2011·1 cites·7 claims
- 4167US2017283775A1Compositions and Methods for Treatment of CancerUNIV PENNSYLVANIA·Filed 2016·Application pending·0 cites
- 4266US2018271907A1Use of cart19 to deplete normal b cells to induce toleranceUNIV PENNSYLVANIA·Filed 2018·Application pending·0 cites
- 4365US2015290244A1Use of cart19 to deplete normal b cells to induce toleranceUNIV PENNSYLVANIA·Filed 2013·Application pending·0 cites
- 4460US2015140019A1Compositions and Methods for Regulating CAR T CellsUNIV PENNSYLVANIA·Filed 2013·Application pending·0 cites
- 4558US2015202286A1Toxicity Management for Anti-Tumor Activity of CARsUNIV PENNSYLVANIA·Filed 2013·Application pending·0 cites
- 4658US2019367610A1Compositions and Methods for Regulating CAR T CellsUNIV PENNSYLVANIA·Filed 2018·Application pending·0 cites
- 4756US2019292257A1Methods of making chimeric antigen receptor - expressing cellsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4854US11896614B2Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cellsNOVARTIS AG·Filed 2016·Granted Feb 13, 2024·0 cites·15 claims
- 4951US2006204500A1Methods for modulating expression of an HIV-1 fusion cofactorJUNE CARL H·Filed 2006·Application pending·0 cites
- 5047US7927595B1Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodiesUS NAVY·Filed 1998·Granted Apr 19, 2011·4 cites·11 claims
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Bruce L. Levine files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →